Skip to main content
Call for Papers
Guidelines for authors
(levonorgestrel-releasing intrauterine system) 52 mg
® (alirocumab) Injection
for FULL PRESCRIBING INFORMATION for PRALUENT.
(insulin degludec injection)
(uridine triacetate) oral granules
for FULL PRESCRIBING INFORMATION for Vistogard.
You are here
Spaces are allowed; punctuation is not allowed except for periods, hyphens, apostrophes, and underscores.
A valid e-mail address. All e-mails from the system will be sent to this address. The e-mail address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by e-mail.
Provide a password for the new account in both fields.
Subscribe to our Newsletter
Our newsletter summarizes the latest drug approvals, industry trends, and clinical trials.
Managed care organization
Government (federal, state, local, military)
Nursing home/Long-term care
Medicare Advantage/Medicare PDP
State Medicaid agency
Other (please indicate)
Are you a prescriber?
Do you serve on a P&T committee?
Are you the chair of your P&T committee?
Formulary Kit Access
If you would like to have access to the formulary kits, you need to be a member of a U.S.-based P&T or formulary committee. Fill in the fields in the shaded area below. Your supervisor’s name and email address are used to verify your role.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Leave this field blank